Cultural differences in unsolicited e-mail advertising, aka SPAM

Hee Sun Park(박희선),Hyeeun Lee,Yoon Sook Shin 한국언론학회 2009 한국언론학회 심포지움 및 세미나 Vol.2009 No.6

Streptococcus parasanguinis에 의한 폐렴과 부폐렴성 흉수

박명린 ( Myoung Rin Park ),박동일 ( Dong Il Park ),유수진 ( Su Jin Yoo ),정선영 ( Sun Young Jung ),은혁수 ( Hyuk Soo Eun ),김민정 ( Min Jung Kim ),박지원 ( Ji Won Park ),박희선 ( Hee Sun Park ),정성수 ( Sung Soo Jung ),김주옥 ( Ju 대한결핵 및 호흡기학회 2011 Tuberculosis and Respiratory Diseases Vol.71 No.5

Streptococcus parasanguinis is a Viridans group bacteria that is most often discovered in the oral cavity and causes dental plaque and endocarditis in a rat model. It has low virulence but an unknown relationship to human respiratory infections. We report on a 61-year-old woman who developed hemoptysis followed by pleuritic chest pain after conscious sedation during a gastroscopic polypectomy and was diagnosed with pneumonia and parapneumonic effusion from Streptococcus parasanguinis isolated in pleural fluid. Microaspiration during the procedure was presumed to play a role in the pathogenesis.

중증 또는 비전형적 지역사회획득 폐렴으로 입원한 환자에서 호흡기 바이러스 의 검출 빈도

박지원 ( Ji Won Park ),정선영 ( Sun Young Jung ),은혁수 ( Hyuk Soo Eun ),천신혜 ( Shin Hye Cheon ),성석우 ( Seok Woo Seong ),박동일 ( Dong Il Park ),박명린 ( Myung Rin Park ),박희선 ( Hee Sun Park ),정성수 ( Sung Soo Jung ),김주옥 대한결핵 및 호흡기학회 2011 Tuberculosis and Respiratory Diseases Vol.71 No.5

Background: Community-acquired pneumonia (CAP) is an important cause of morbidity and mortality throughout the world in all age groups. Viral causes of CAP are less well characterized than bacterial causes. We analyzed the characteristics of hospitalized patients with CAP who had a viral pathogen detected by multiplex polymerase chain reaction (PCR). Methods: Multiplex real-time PCR was performed for respiratory viruses in samples collected from 520 adults who developed CAP at Chungnam National University Hospital. Clinical, laboratory, and radiological features at presentation as well as other epidemiological data were analyzed. Results: Of 520 patients with CAP, a viral pathogen was detected in 60 (11.5%), and influenza A was the most common. The virus detection rate in patients with CAP was highest in November. Two or more pathogens were detected in 13 (21.7%) patients. Seven patients had severe disease and were administered in the intensive care unit. Most patients (49/60, 81.7%) had comorbidities. However, nine (15%) patients had no comorbidities, and their age was <60 years. The ground glass opacity pattern was the most common radiological feature. Seven (11.7%) patients died from CAP. Conclusion: Viral pathogens are commonly detected in patients with CAP, and a respiratory virus may be associated with the severity and outcome of pneumonia. Careful attention should be paid to the viral etiology in adult patients with CAP.

대학생을 위한 금융상품 개발

이희숙(Hee Sook Lee),김성은(Sung Eun Kim),박희선(Hee Sun Park),이미경(Mie Kyung Lee) 충북대학교 생활과학연구소 2007 생활과학연구논총 Vol.11 No.2

  This Study was to find the way to develop financial products for university students" sake. Questionnaire survey was conducted from July 12, 2006 to July 19 and 286 university students were selected. Major findings were as follows;<BR>  First, the developing of financial product without paper statement and with considerable interest rate may be suggested for university students, and the developing of financial product for only internet use may be suggested as well.<BR>  Second, the developing of financial products with special services such as applying discount rate for money transfer or ATM machine use, movie(or musical)ticket buying services as a discount rate, and different services from non-university students may be suggested.<BR>  Third, it may be suggested that 1) the developing of MMDA with minimum deposit 100,000 Won and considerable interest rate; 2) the developing of MMF with investment safety and money transfer freely; 3) the developing of CMA with investment safety.<BR>  Fourth, the developing of university loan which students can pay back by themselves when they get a job2008년 1월 3일 after their graduation may be suggested.

Phase II Study of Induction Irinotecan + Cisplatin Chemotherapy Followed by Concurrent Irinotecan + Cisplatin Plus Twice-Daily Thoracic Radiotherapy

이정은,박희선,정성수,김주옥,조문준,김진환,이충식,김선영,Lee, Jeong Eun,Park, Hee Sun,Jung, Sung Soo,Kim, Ju Ock,Cho, Moon June,Kim, Jin Hwan,Lee, Choong Sik,Kim, Sun Young The Korean Academy of Tuberculosis and Respiratory 2007 Tuberculosis and Respiratory Diseases Vol.63 No.2

배경: Irinotecan hydrochloride는 topoisomerase I inhibitor로서 소세포 폐암에 효과적인 약제로 알려져 있다. Irinotecan은 cisplatin과 더불어 방사선감작물질로 작용하기도 한다. 본 연구는 이전에 치료받은 경험이 없는 제한성 병기의 소세포 폐암 환자에서 irinotecan과 cisplatin(IP)의 방사선 동시화학요법의 효과를 평가하기 위하여 시행되었다. 방법: 2002년 12월부터 2004년 11월까지 충남대학교 병원에서 새로이 제한성 병기의 소세포 폐암으로 진단된 24명의 환자들을 대상으로 하였다. Irinotecan $60mg/m^2$을 제 1일과 제 8일째 투여하였고 cisplatin $60mg/m^2$을 제 1일째 투여하였으며 매 3주 간격으로 시행되었다. 제 3차 항암화학요법을 시작하는 날과 동시에 과다 분할방사선 치료(twice-daily thoracic irradiation; 45 Gy total)을 시작하였다. 예방적 전 뇌 방사선 조사(Prophylactic cranial irradiation)가 방사선 동시화학요법이 끝난 후 완전반응(complete response)을 나타낸 환자에서 시행되었다. 제 2차 항암요법과 제 6차 항암요법이 끝난 후에 흉부 전산화 단층촬영과 기관지경 등을 통한 병기의 재평가가 이루어졌다. 결과: 병기의 재평가는 19명의 환자에게 이루어졌다. 중앙 추적관찰기간은 12.5개월이고 전체 99회의 항암치료가 시행되었다. 평균 한 환자당 5.2회의 항암치료가 시행되었다. 실제 용량강도는 cisplatin $19.6mg/m^2$/week과 irinotecan $38.2mg/m^2$/week이었다. 9명의 환자가 완전반응을 보였고 10명의 환자가 부분반응(partial response)을 보여서 전체 반응률은 95%였다. 3에서 4도의 혈액학적 독성은 백혈구 감소증(35% of cycles), 빈혈(7% of cycles), 혈소판 감소증(7% of cycles) 등으로 나타났다. 3에서 4도의 비 혈액학적 독성은 설사(5% of cycles)였다. 3에서 4도의 방사선 식도염(10% of patients)을 제외하고는 과다 분할 방사선 치료를 이용한 방사선 동시 화학요법의 기존의 방법과 독성 면에서는 큰 차이가 없었다. 치료와 관련된 사망은 관찰되지 않았다. 평가가 가능한 환자들에서 1년 생존율과 2년 생존율은 각각 89% (16/18)와 47% (9/18)였다. 결론: 3주 간격으로 시행된 irinotecan과 cisplatin을 이용한 과다분할 방사선 동시 요법은 제한성 병기의 소세포 폐암 환자에서 부작용은 높지 않으면서 효과적인 치료법으로 고려될 수 있을 것이다. Background: Irinotecan hydrochloride, a topoisomerase I inhibitor, is effective against small-cell lung cancer. Irinotecan also can act as a potential radiation sensitizer along with cisplatin. To evaluate efficacy and toxicity of irinotecan plus cisplatin (IP) with concurrent thoracic radiotherapy, we conducted a phase II study of IP followed by concurrent IP plus hyperfractionated thoracic radiotherapy in patients with previously untreated limited-stage small-cell lung cancer. Methods: Twenty-four patients with previously untreated small-cell lung cancer were enrolled onto the study since November 2004. Irinotecan $60mg/m^2$ was administered intravenously on days 1 and 8 in combination with cisplatin $60mg/m^2$ on day1 every 21 days. From the first day of third cycle, twice-daily thoracic irradiation (total 45 Gy) was given. Prophylactic cranial irradiation was given to the patients who showed complete remission after concurrent chemoradiotherapy. Restaging was done after second and sixth cycle with chest CT and/or bronchosocpy. Results: Up to November 2004, 19 patients were assessable. The median follow-up time was 12.5 months. A total of 99 cycles (median 5.2 cycles per patient) were administered. The actual dose intensity values were cisplatin $19.6mg/m^2$/week and irinotecan $38.2mg/m^2$/week. Among the 19 patients, the objective response rate was 95% (19 patients), with 9 patients (47%) having a complete response (CR). The major grade 3/4 hematological toxicities were neutropenia (35% of cycles), anemia (7% of cycles), thrombocytopenia (7% of cycles). Febrile neutropenia was 4% of cycles. The predominant grade 3/4 non-hematological toxicities was diarrhea (5% of cycles). Toxicities was not significantly different with concurrent administration of irinotecan and cisplatin with radiotherapy, except grade 3/4 radiation esophagitis (10% of patients). No treatment-related deaths were observed. The 1-year and 2-year survival rate of eligible patients was 89% (16/18) and 47% (9/18), respectively. Conclusion: Three-week schedule of irinotecan plus cisplatin followed by concurrent IP plus hyperfractionated thoracic radiotherapy is an effective treatment for limited disease small-cell lung cancer, with acceptable toxicity.

자가 형광 기관지 내시경을 이용한 동시성 원발성 폐암의 진단

권선중 ( Sun Jung Kwon ),이연선 ( Yun Seun Lee ),정미경 ( Mi Kyong Joung ),이유진 ( Yu Jin Lee ),장필순 ( Pil Soon Jang ),이정은 ( Jeung Eyun Lee ),정재욱 ( Chae Uk Chung ),박희선 ( Hee Sun Park ),정성수 ( Sung Soo Jung ),김선영 ( 대한결핵 및 호흡기학회 2006 Tuberculosis and Respiratory Diseases Vol.60 No.6

연구 배경: 새로이 폐암으로 진단되는 환자에 대하여 기존 백색빛 기관지 내시경 검사에 더하여 자가 형광 기관지 내시경 시행 시, 2차성 동시성 원발성 폐암 및 전암성 병변의 발견율 향상의 정도를 알아 보고자 연구를 계획하였다. 방법: 2005년 1월부터 12월까지 충남대학교 병원에서 폐암으로 진단되는 환자를 대상으로 백색빛 기관지 내시경 시행 후 날짜를 달리하여 형광기관지 내시경을 시행하여, 원발성 병변과는 해부학적으로 다른 부위에 내시경 소견상 이상이 있는 경우 모두 조직검사를 시행하여 확인하였다. 결과: 새로이 폐암으로 진단되는 99명에 대하여 백색빛 기관지 내시경 및 자가 형광 기관지 내시경이 시행되었고, 이들 중 46명의 환자에 대하여 84곳의 조직검사가 시행되었다. 이차성 암성 병변의 경우 6명의 환자에서 확인이 가능하였고, 이중 동시성 폐암으로 판단한 환자는 4명(4.0%)으로 모두 절제 불가능한 1차성 병변을 가지고 있는 환자이었고, 전이성 폐암으로 판단한 환자는 2명(2.0%)이었으며, 이 중 한명은 IIIB병기에서 IV병기로 병기상승을 가져왔다. 전암성 병변인 중증 이형성증은 초기 절제 가능한 비소세 폐암 환자 중 2명, 절제 불가능한 비소세포 폐암 환자 중 1명, 1명의 소세포 폐암 환자에서 발견 되었다(4/99, 4.0%). 자가 형광 기관지 내시경 시행 전과 후의 발견율의 차이는, 이차성 암성 병변의 경우 3명(3%)에서 6명(6%)으로, 동시성 폐암만 살펴 보았을 경우 2명(2.0%)에서 4명(4.0%)으로 향상되었고, 중증 이형성증은 모두 자가 형광 기관지 내시경 시행 후에만 발견되었다. 이러한 이차성 암성 병변이 치료에 미치는 영향은 거의 없었는데, 이는 대부분이 수술적 치료가 불가능한 진행된 1차성 병변을 가진 환자에서 발견되었기 때문이었다. 결론: 자가 형광 기관지 내시경은 2차성 초기 암성내지 전암성 병변의 발견율 향상에는 백색빛 기관지 내시경 단독 검사보다 우수하나, 전체 폐암환자에서 진단 시 치료에 미치는 영향은 미미하였다. Objective: Patients with lung cancer have a relative high risk of developing secondary primary lung cancers. This study examined the additional value of autofluorescence bronchoscopy (AFB) for diagnosing synchronous lung cancers and premalignant lesions. Methods: Patients diagnosed with lung cancer from January 2005 to December 2005 were enrolled in this study. The patients underwent a lung cancer evaluation, which included white light bronchoscopy (WLB), followed by AFB. In addition to the primary lesions, any abnormal or suspicious lesions detected during WLB and AFB were biopsied. Results: Seventy-six patients had non-small cell lung cancer (NSCLC) and 23 had small cell lung cancer (SCLC). In addition to the primary lesions, 84 endobronchial biopsies were performed in 46 patients. Five definite synchronous cancerous lesions were detected in three patients with initial unresectable NSCLC and in one with SCLC. The secondary malignant lesions found in two patients were considered metastatic because of the presence of mediastinal nodes or systemic involvement. One patient with an unresectable NSCLC, two with a resectable NSCLC, and one with SCLC had severe dysplasia. The detection rate for cancerous lesions by the clinician was 6.0% (6/99) including AFB compared with 3.0% (3/99) with WLB alone. The prevalence of definite synchronized cancer was 4.0% (4/99) after using AFB compared with 2.0% (2/99) before, and the staging-up effect was 1.0% (1/99) after AFB. Since the majority of patients were diagnosed with advanced disease, the subjects with newly detected cancerous lesions did not have their treatment plans altered, except for one patient with a stage-up IV NSCLC who did not undergo radiotherapy. Conclusions: Additional AFB is effective in detecting early secondary cancerous lesions and is a more precise tool in the staging workup of patients with primary lung cancer than with WLB alone. (Tuberc Respir Dis 2006; 60: 645-652)

경동맥화학색전술 불응성인 Child-Pugh Class A 간세포암 환자의 간기능 악화에 대한 위험인자

박강현 ( Kang Hyun Park ),김정한 ( Jeong Han Kim ),최원혁 ( Won Hyeok Choe ),권소영 ( So Young Kwon ),유병철 ( Byung Chul Yoo ),황진호 ( Jin Ho Hwang ),박상우 ( Sang Woo Park ),김영준 ( Young Jun Kim ),박희선 ( Hee Sun Park ),유 대한소화기학회 2020 대한소화기학회지 Vol.75 No.3

Background/Aims: A switch to systemic therapy, such as sorafenib, should be considered for hepatocellular carcinoma (HCC) pa­tients refractory to transarterial chemoembolization (TACE). On the other hand, treatment changes are difficult if the liver function worsens to Child-Pugh B or C. Therefore, predicting the risk factors for non-responsiveness to TACE and deteriorating liver function may be helpful. Methods: Newly diagnosed Child-Pugh A HCC patients who underwent TACE from January 2012 to June 2018 were included. After 1 year, this study evaluated whether there was a treatment response to TACE and whether the Child-Pugh class had worsened. Results: Among 121 patients, 65 were refractory and 56 responded to TACE. In multivariable logistic regression analysis, the tu­mor size, tumor number, and albumin at the time of the diagnosis of HCC were significant prognostic factors for the treatment re­sponse to TACE. Among 65 patients who presented TACE-refractoriness, 27 showed liver function deterioration from Child-Pugh class A to class B or C after TACE. In multivariable logistic regression analysis, bilirubin at the diagnosis of HCC was a significant prognostic factor for liver function deterioration. A predictive algorithm based on the regression equations revealed a sensitivity, specificity, positive predictive value, and negative predictive value of 74.1%, 74.5%, 45.5%, and 90.9%, respectively, for TACE-re­fractoriness and liver function deterioration. Conclusions: The prognostic model incorporating the tumor size, tumor number, albumin, and bilirubin at the diagnosis of HCC may help identify patients who show a poor response to TACE and aggravation of liver function after TACE, who may benefit from early switching into systemic therapy before liver function aggravation.

페결핵이 동반된 페격리증

신지영 ( Ji Young Shin ),박희선 ( Hee Sun Park ),유수진 ( Su Jin Yoo ),정선영 ( Sun Young Jung ),박지원 ( Ji Won Park ),김주옥 ( Ju Ock Kim ),김선영 ( Sung Young Kim ),이정은 ( Jeong Eun Lee ) 대한결핵 및 호흡기학회 2011 Tuberculosis and Respiratory Diseases Vol.70 No.1

Pulmonary sequestration is a rare anomaly, in which a local area of a lung is supplied separately by an anomalous artery that arises from the aorta or one of its branches. Infection, mainly bacterial, is a major complication of sequestration. We report the case of a 17-year-old male patient, who presented with cough and fever. The contrast-enhanced chest computer tomomgraphy (CT) scans revealed an aberrant artery that originated from the descending thoracic aorta. He underwent a left-lower lobectomy. Macroscopically, the abnormal segment presented as multiple heterogenous cystic and solid lesions, and the cysts were filled with mucoid and pus-like material. Histology showed that the pulmonary parenchyma had been replaced by caseating epitheloid granulomas. The mycobacterial culture of his sputum was positive. On the basis of these results, the diagnosis of tuberculosis was established. The patient was treated with anti-tuberculous medication for 6 months, and 1 year later, his clinical status remained excellent.

유제한성 병기의 소세포 폐암에서 3주 간격으로 시행된 irinotecan과 cisplatin을 이용한 과다분할 방사선 동시 요법

이정은 ( Jeong Eun Lee ),박희선 ( Hee Sun Park ),정성수 ( Sung Soo Jung ),김주옥 ( Ju Ock Kim ),조문준 ( Moon June Cho ),김진환 ( Jin Hwan Kim ),이충식 ( Choong Sik Lee ),김선영 ( Sun Young Kim ) 대한결핵 및 호흡기학회 2007 Tuberculosis and Respiratory Diseases Vol.63 No.2

배경: Irinotecan hydrochloride는 topoisomerase I inhibitor로서 소세포 폐암에 효과적인 약제로 알려져 있다. Irinotecan은 cisplatin과 더불어 방사선감작물질로 작용하기도 한다. 본 연구는 이전에 치료받은 경험이 없는 제한성 병기의 소세포 폐암 환자에서 irinotecan과 cisplatin(IP)의 방사선 동시화학요법의 효과를 평가하기 위하여 시행되었다. 방법: 2002년 12월부터 2004년 11월까지 충남대학교 병원에서 새로이 제한성 병기의 소세포 폐암으로 진단된 24명의 환자들을 대상으로 하였다. Irinotecan 60 mg/m2을 제 1일과 제 8일째 투여하였고 cisplatin 60 mg/m2을 제 1일째 투여하였으며 매 3주 간격으로 시행되었다. 제 3차 항암화학요법을 시작하는 날과 동시에 과다 분할방사선 치료(twice-daily thoracic irradiation; 45 Gy total)을 시작하였다. 예방적 전 뇌 방사선 조사(Prophylactic cranial irradiation)가 방사선 동시화학요법이 끝난 후 완전반응(complete response)을 나타낸 환자에서 시행되었다. 제 2차 항암요법과 제 6차 항암요법이 끝난 후에 흉부 전산화 단층촬영과 기관지경 등을 통한 병기의 재평가가 이루어졌다. 결과: 병기의 재평가는 19명의 환자에게 이루어졌다. 중앙 추적관찰기간은 12.5개월이고 전체 99회의 항암치료가 시행되었다. 평균 한 환자당 5.2회의 항암치료가 시행되었다. 실제 용량강도는 cisplatin 19.6 mg/m2/week과 irinotecan 38.2 mg/m2/week이었다. 9명의 환자가 완전반응을 보였고 10명의 환자가 부분반응(partial response)을 보여서 전체 반응률은 95%였다. 3에서 4도의 혈액학적 독성은 백혈구 감소증(35% of cycles), 빈혈(7% of cycles), 혈소판 감소증(7% of cycles) 등으로 나타났다. 3에서 4도의 비 혈액학적 독성은 설사(5% of cycles)였다. 3에서 4도의 방사선 식도염(10% of patients)을 제외하고는 과다 분할 방사선 치료를 이용한 방사선 동시 화학요법의 기존의 방법과 독성 면에서는 큰 차이가 없었다. 치료와 관련된 사망은 관찰되지 않았다. 평가가 가능한 환자들에서 1년 생존율과 2년 생존율은 각각 89% (16/18)와 47% (9/18)였다. 결론: 3주 간격으로 시행된 irinotecan과 cisplatin을 이용한 과다분할 방사선 동시 요법은 제한성 병기의 소세포 폐암 환자에서 부작용은 높지 않으면서 효과적인 치료법으로 고려될 수 있을 것이다. (Tuberc Respir Dis 2007; 63: 154-164) Background: Irinotecan hydrochloride, a topoisomerase I inhibitor, is effective against small-cell lung cancer. Irinotecan also can act as a potential radiation sensitizer along with cisplatin. To evaluate efficacy and toxicity of irinotecan plus cisplatin (IP) with concurrent thoracic radiotherapy, we conducted a phase II study of IP followed by concurrent IP plus hyperfractionated thoracic radiotherapy in patients with previously untreated limited-stage small-cell lung cancer. Methods: Twenty-four patients with previously untreated small-cell lung cancer were enrolled onto the study since November 2004. Irinotecan 60 mg/m2 was administered intravenously on days 1 and 8 in combination with cisplatin 60 mg/m2 on day1 every 21 days. From the first day of third cycle, twice-daily thoracic irradiation (total 45 Gy) was given. Prophylactic cranial irradiation was given to the patients who showed complete remission after concurrent chemoradiotherapy. Restaging was done after second and sixth cycle with chest CT and/or bronchosocpy. Results: Up to November 2004, 19 patients were assessable. The median follow-up time was 12.5 months. A total of 99 cycles (median 5.2 cycles per patient) were administered. The actual dose intensity values were cisplatin 19.6 mg/m2/week and irinotecan 38.2 mg/m2/week. Among the 19 patients, the objective response rate was 95% (19 patients), with 9 patients (47%) having a complete response (CR). The major grade 3/4 hematological toxicities were neutropenia (35% of cycles), anemia (7% of cycles), thrombocytopenia (7% of cycles). Febrile neutropenia was 4% of cycles. The predominant grade 3/4 non-hematological toxicities was diarrhea (5% of cycles). Toxicities was not significantly different with concurrent administration of irinotecan and cisplatin with radiotherapy, except grade 3/4 radiation esophagitis (10% of patients). No treatment-related deaths were observed. The 1-year and 2-year survival rate of eligible patients was 89% (16/18) and 47% (9/18), respectively. Conclusion: Three-week schedule of irinotecan plus cisplatin followed by concurrent IP plus hyperfractionated thoracic radiotherapy is an effective treatment for limited disease small-cell lung cancer, with acceptable toxicity.

폐결핵 진단을 위한 STAT-PAK ULTRA FAST(R)와 ICT Tuberculosis(R)의 유용성에 관한 연구

김근화 ( Geun Hwa Kim ),박희선 ( Hee Sun Park ),김명훈 ( Myung Hoon Kim ),강동원 ( Dong Won Kang ),이규승 ( Kyu Seung Lee ),고동석 ( Dong Seok Ko ),서재철 ( Jae Chul Suh ),정성수 ( Seong Su Jeong ),김주옥 ( Ju Ock Kim ),김선영 ( S 대한결핵 및 호흡기학회 1999 Tuberculosis and Respiratory Diseases Vol.47 No.3